Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
HLA class I histocompatibility antigen, A alpha chain (specifically the A*02 serotype) is a critical component of the Major Histocompatibility Complex (MHC) class I system, responsible for presenting endogenous peptides to CD8+ cytotoxic T lymphocytes (CTLs) [UniProt: P01892]. It consists of a polymorphic alpha chain non-covalently associated with beta-2 microglobulin, forming a groove that binds peptides derived from intracellular proteins [NCBI Gene: 3105]. This molecule is essential for the immune system to distinguish between self and non-self, as well as for the detection of virally infected or malignant cells. In modern oncology, HLA-A*02 is a primary focus for immunotherapy because it is one of the most prevalent HLA alleles in the Caucasian population, making it a key target for TCR-engineered T-cell therapies and bispecifics like Tebentafusp [FDA: Kimmtrak Label]. These therapies are designed to recognize specific tumor-associated antigens presented by HLA-A*02, such as gp100 or NY-ESO-1 [: NCT03645928]. However, therapeutic efficacy can be limited by tumor-mediated HLA downregulation or the risk of off-target toxicity if the TCR cross-reacts with similar peptides presented on healthy tissues. Furthermore, the high polymorphism of the HLA-A gene necessitates precise patient HLA typing to ensure treatment compatibility.
Presentation of specific intracellular peptides to CD8+ T-cells to initiate immune-mediated cell death; TCR-based therapies and bispecifics bind to the peptide-HLA complex to trigger T-cell activation against target cells [FDA: Kimmtrak Label; ].
5 more in the full profile.
Source types: Peer-reviewed publication · Trial registry. Sources are available to Gosset users. Log in to see them.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on HLA class I histocompatibility antigen, A alpha chain (HLA-A*02) (HLA-A*02).